---
title: "BioMarin spends up to $490m for Alesta’s bone disease candidate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296381315.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-08-19T13:55:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296381315.md)
  - [en](https://longbridge.com/en/news/296381315.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296381315.md)
generator: "portal-rs"
---

# BioMarin spends up to $490m for Alesta’s bone disease candidate

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)

## Related News & Research

- [BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment](https://longbridge.com/en/news/296376333.md)
- [Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia](https://longbridge.com/en/news/296228796.md)
- [Fulcrum and Slate Medicines sign merger agreement](https://longbridge.com/en/news/296206650.md)
- [Kynexis pockets €97m to advance cognition-focused schizophrenia drug](https://longbridge.com/en/news/296501085.md)
- [Enrolment concludes in Lynch’s Phase II rhPDGF-BB study](https://longbridge.com/en/news/296343171.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**